



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/647,789	08/25/2003	Daniel P. Wermeling	INT-001 B	2016
51414	7590	07/29/2008	EXAMINER	
GOODWIN PROCTER LLP			BETTON, TIMOTHY E	
PATENT ADMINISTRATOR				
EXCHANGE PLACE			ART UNIT	PAPER NUMBER
BOSTON, MA 02109-2881			1617	
			NOTIFICATION DATE	DELIVERY MODE
			07/29/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PatentBos@goodwinprocter.com
hmcppeake@goodwinprocter.com
glenn.williams@goodwinprocter.com

Office Action Summary	Application No.	Applicant(s)
	10/647,789	WERMELING, DANIEL P.
	Examiner	Art Unit
	TIMOTHY E. BETTON	1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 09 July 2007.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 53-67 and 70-72 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 53-67 and 70-72 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ . |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ . | 6) <input type="checkbox"/> Other: _____ . |

DETAILED ACTION

Applicants Remarks filed on 17 April 2008 have been acknowledged and duly made of record.

The essence of applicants arguments are drawn to the art-recognized parameters used to characterize liquid spray plumes. An explanation of the meaning of “Dv” values are adequately elucidated in applicants' response and the 112, 2nd paragraph rejection over claims 53-67 and 70 - 72 are hereby withdrawn.

Further, applicants' aver on the properness of the 103(a) rejection as applied to claims 53-59 and 62-67, 70 and 71.

Principally, applicants disclose a number of embodiments within the instant claims drawn to common function(s) of an intranasal unit-dose delivery device (i.e., **wherein upon positioning the device [[1]] 5cm away from a laser beam detection pathway, actuating the device to produce a spray plume perpendicular to said pathway, and detecting droplet size distribution of the spray plume with said laser beam detection pathway**, the spray plume has a Dv10 of from about 14.3 ~tm to about 17.1 gm and a Dv50 of from about 31.0 gm to about 35.3 μ m.

The 103(a) rejection drawn to the references already made of record teach aspects of the claimed invention. However, they do not teach the limitations of the claims drawn specifically to *one or more sealed vessels containing a sterilized, preservative -free pharmaceutical composition.*

Rejections and/or objections not reiterated from previous Office Actions are hereby withdrawn. The following rejections and/or rejections are either reiterated or newly applied.

Claim Rejections- 35 U.S.C. 103(a)

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.


Claims 53-59 and 62-67, 70, and 71 are rejected under 35 U.S.C. 103(a) as being unpatentable over Weinstein et al. (USPN 5437267) and Levin, B. (PGPUB US 2001/0004644 A1) in view of Ward-Smith, S., (Semi-automated testing of nasal sprays. (Nasal Spray Testing, Pharmaceutical Technology Europe, (2002), pages 1-9).

For evidentiary purposes, applicant discloses butorphanol tartrate in instant claims 54 and 71 which has an intranasal delivery formulation device system called Stadol NS®, Bristol-Myers Squibb in 1991 was approved by the FDA for marketing as a prescription medication (A Brief History of Bristol-Myers Squibb, 2007, Newsroom, page 3, 8th paragraph).

Additionally for evidentiary purposes:

Butorphanol tartrate is a synthetically derived opioid agonist-antagonist analgesic of the phenanthrene series. The chemical name is (-)-17-(cyclobutylmethyl) morphinan- 3, 14- diol [S-(R*, R*)] - 2,3 - dihydroxybutanedioate (1: 1) (salt). The molecular formula is C21H29 NO2,

C₄H₆O₆, which corresponds to a molecular weight of 477.55 and the following structural formula:



Butorphanol tartrate is a white crystalline substance. The dose is expressed as the tartrate salt. One milligram of the salt is equivalent to 0.68 mg of the free base. The n-octanol/aqueous buffer partition coefficient of butorphanol is 180:1 at pH 7.5.

STADOL NS (butorphanol tartrate) is an aqueous solution of butorphanol tartrate for administration as a metered spray to the nasal mucosa. Each bottle of STADOL NS contains 2.5 mL of a 10-mg/mL solution of butorphanol tartrate with sodium chloride, citric acid, and benzethonium chloride in purified water with sodium hydroxide and/or hydrochloric acid added to adjust the pH to 5.0. The pump reservoir must be fully primed (see PATIENT INSTRUCTIONS in HOW SUPPLIED) prior to initial use. After initial priming each metered spray delivers an average of 1.0 mg of butorphanol tartrate and the 2.5 mL bottle will deliver an average of 14–15 doses of STADOL NS. If not used for 48 hours or longer, the unit must be reprimed (see PATIENT INSTRUCTIONS in HOW SUPPLIED). With intermittent use requiring repriming before each dose, the 2.5 mL bottle will deliver an average of 8–10 doses of STADOL NS depending on how much repriming is necessary. (RXLIST monographs; The Internet Drug Index, (2007), Butorphanol Tartrate; Description, pages 1 and 2). Above reference

discloses general specifications which are obvious over the subject matter in applicant's invention in that an opioid intranasal delivery device is taught with ingredients that are not identical but contain similar constituents as disclosed in instant claims.

Weinstein et al. teach a device for the intranasal delivery of a medicament regimen to the nasal membranes for the treatment of such conditions as rhinitis (Abstract). Referenced Figure 1A depicts a perspective view of another embodiment of invention including 2 (in comparison to 1 or more claimed in instant claim 53) medicament canisters/chambers. The term chamber is interchangeable with the term vessel of instant claim 53. All other depictions for Figures 2 through Figure 7 incorporate the use of more than two medicament canisters with variations in configuration thereof for optimal therapeutic delivery (Drawing sheets 1-3, columns 3-8).

Weinstein et al. does not teach use of an opioid formulation in referenced device. Additionally, Weinstein et al. does not teach a description of spray plume actuation or volume median measurements in terms of D_v parameters.

Levin teaches the practicing methods comprising intranasally administering to the patient a pharmaceutical composition comprising a local anesthetic. Levin further discloses butorphanol tartrate for use in intranasal device for muscular headaches (page 2, section [0018]; page 21, section [0200]; page 39, claim 24).

However, Levin, too, does not teach a description of spray plume actuation or volume median measurements in terms of D_v parameters.

However, Ward-Smith, which teaches nasal spray formulations consist[ing] of the drug suspended or dissolved in an aqueous medium, which is filled into a bottle with a metered spray pump. Pump actuation by the patient delivers the drug in fine droplets into the nasal cavity. The

pump is an integral part of the whole assembly and plays a crucial role in delivering an accurate dose to the correct absorption site. Of particular importance is the droplet size distribution produced by the pump, which must be optimized to increase nasal deposition and minimize lung deposition or absorption in the gastrointestinal tract (page 1, 1st paragraph). Further, Ward-Smith encompasses the spray droplet size ranges disclosed by instant claims with a description of the Spraytec with Nasal spray Actuator with a 200mm Fourier lens, [which] is [...] most typically used in this application, allowing measurements in the 1-400 [micro]m size range.

Further, Ward-Smith teaches the measurements at three different distances between the laser diffraction measurement zone and the tip of the pump (measurements of 3,6, and 9 cm) (page 3, Experimental, 4th sentence). Independent claim 53 and dependent claims 62-70 discloses a positioning of the device 1 cm and 5 cm away, respectively from a laser detection pathway. Ward-Smith teaches nasal spray formulations consist[ing] of a drug suspended or dissolved in an aqueous medium same as disclosed in instant claim 58. Laser diffraction as a technique for particle sizing is taught (page 2 and 3, Droplet sizing using laser diffraction). Multiple measurements are required for each measurement point to assess the measurement precision. The 10th, 50th and 90th percentiles (Dv10, Dv50 and Dv90) must be reported for the size distributions measured during each stage. The span of the size distribution must also be reported ($\text{Span} = [\text{Dv90} - \text{Dv10}/\text{Dv50}]$) according to Ward-Smith et al. (pg 3, Experimental, 5th sentence). Instant claims 63 and 64 are obvious in view of Ward-Smith. Referenced page 6-8 teaches actual result data obtained for manual actuation pumps and as a function of pressure (semi-automated) pumps. The reference discloses ranges higher in comparison to instant claimed

ranges with the exception of some examples of conclusive data. One of ordinary skill in the pertinent art would at once recognize the necessity to properly adjust the ranges.

It, therefore, would be *prima facie* obvious to modify the device and medicament administered in Weinstein et al. to an opioid. Accordingly, it would be obvious to modify the device of Levin, which does teach a practicing administration of butorphanol tartrate in an intranasal device. The motivation to combine would be obvious based in view of Ward-Smith, which does teach the specific parameters of efficacious administration, i.e., description of spray plume actuation, the detection of droplet size distribution, specific droplet size, etc.

Claims 60, 61 and 72 are rejected under 35 U.S.C. 103(a) as being unpatentable over Claims 53-59 and 62-67, 70, and 71 are rejected under 35 U.S.C. 103(a) as being unpatentable over Weinstein et al. (USPN 5437267) and Levin, B. (PGPUB US 2001/0004644 A1) in view of Ward-Smith, S. as applied to claim 53-59 and 62-67, 70, and 71 above, and further in view of Illum et al. (Intranasal Delivery of Morphine, *The Journal of Pharmacology and Experimental Therapeutics*, 2001, vol.301, no.1, pages 391-400), Pezron et al. (Prodrug strategies in nasal drug delivery, *Expert Opin. Ther. Patents* (2002) 12(3): 331-340), and Manjushree et al. (Intranasal fentanyl provides adequate postoperative analgesia in pediatric patients, *CAN J ANESTH* 2001, 49:2, pages 190-193) in view of Midha et al. (USPN 6127385).

Illum et al. teach the intranasal delivery of morphine, a potent narcotic analgesic, [which] produces a variety of pharmacological responses by interacting with the opioid receptors in the nervous system (page 391, 1st paragraph). Further, Illum et al. teach butorphanol as a practicing analgesic agent that can be effectively and rapidly absorbed from the nasal cavity (page 391, 3rd

paragraph). Additionally, Illum et al. teach a pH range of 4.02 and 3.81, respectively which are specific to the broad pH range (pH of about 3 to about 6) disclosed in instant independent claim 53 (page 392, Formulation Preparation, 2nd and 3rd paragraph).

Illum et al. does not teach the intranasal opioid formulation with citrate buffered water or a sweetener. Illum et al. teach said formulation with an absorption-promoting agent such as chitosan.

Pezron et al. teach strategies for enhanced nasal drug delivery via taste modification of these bitter moieties by use with moieties that lack bitterness (page 337, Miscellaneous applications, 2nd paragraph).

Pezron et al. does not teach nasal drug formulation with a sweetener to mask the bitter taste due to administration.

Manjushree et al. teach the well-established use of the intranasal opioid fentanyl with the nasal carrier citrate in the formulation (page 191). Further, Manjushree et al. teach the scope of prolonged use of fentanyl citrate without any adverse effects.

Manjushree et al. does not teach an intranasal opioid with a sweetener or flavoring agent.

However, the Examiner refers to Midha et al., which teach an embodiment of a nasal formulation containing [active agent] dissolved in aqueous or non-aqueous solvent, an antioxidant and aromatic oils as flavoring agents (column 4, lines 59 to 63). In instant claim 61, aromatic oils are disclosed as rosemary oil, spearmint oil, thyme oil, etc. Instant claim 72 specifically discloses sucrose, but Midha et al. does not teach sucrose. However, it would have been obvious to interchange flavoring agents based on the list disclosed within instant claim 61.

Further, in view of the limitations drawn specifically to *one or more sealed vessels containing a sterilized, preservative -free pharmaceutical composition*, the MPEP cites thus:

**Omission of an Element and Its Function Is Obvious if the Function of the Element Is
Not Desired**

Ex parte Wu , 10 USPQ 2031 (Bd. Pat. App. & Inter. 1989) (Claims at issue were directed to a method for inhibiting corrosion on metal surfaces using a composition consisting of epoxy resin, petroleum sulfonate, and hydrocarbon diluent. The claims were rejected over a primary reference which disclosed an anticorrosion composition of epoxy resin, hydrocarbon diluent, and polybasic acid salts wherein said salts were taught to be beneficial when employed in a freshwater environment, in view of secondary references which clearly suggested the addition of petroleum sulfonate to corrosion inhibiting compositions. The Board affirmed the rejection, holding that it would have been obvious to omit the polybasic acid salts of the primary reference where the function attributed to such salt is not desired or required, such as in compositions for providing corrosion resistance in environments which do not encounter fresh water.). See also In re Larson, 340 F.2d 965, 144 USPQ 347 (CCPA 1965) (Omission of additional framework and axle which served to increase the cargo carrying capacity of prior art mobile fluid carrying unit would have been obvious if this feature was not desired.); and In re Kuhle, 526 F.2d 553, 188 USPQ 7 (CCPA 1975) (deleting a prior art switch member and thereby eliminating its function was an obvious expedient).

**B. Omission of an Element with Retention of the Element's Function Is an Indicia of
Unobviousness**

Note that the omission of an element and retention of its function is an indicia of unobviousness. In re Edge, 359 F.2d 896, 149 USPQ 556 (CCPA 1966) (Claims at

issue were directed to a printed sheet having a thin layer of erasable metal bonded directly to the sheet wherein said thin layer obscured the original print until removal by erasure. The prior art disclosed a similar printed sheet which further comprised an intermediate transparent and erasure-proof protecting layer which prevented erasure of the printing when the top layer was erased. The claims were found unobvious over the prior art because the although the transparent layer of the prior art was eliminated, the function of the transparent layer was retained since appellant's metal layer could be erased without erasing the printed indicia.).

Thus, it would be *prima facie* obvious to the one of skill at the time of the invention to recognize a reasonable expectation of success via the combining and incorporating together of the teachings, methods and modification of Weinstein, Levin, and Ward-Smith, principally. Weinstein teaches embodiments drawn to variable intranasal devices, which adequately encompasses the device as claimed of current invention. The deficiency in Weinstein is resolved by Levin, which teaches the practicing methods comprising the intranasal administration of the bioactive agent butorphanol tartrate. Ward-Smith further cures the deficiency of Levin by teaching the mechanics behind the optimal spray plumb for increased therapeutic efficacy into the nasal passages. The common measurement referred to as Dv's are adequately elucidated in the reference in obviousness over the claimed invention.

Further, Illum, Pezron, Manjushree and Midha teach the limitations as drawn to the present claims in reference to pH, sweeteners, nasal citrate carriers, flavoring agents, respectively. Accordingly, in addition to the references cited as in further view of the limitations of claim *one or more sealed vessels containing a sterilized, preservative -free pharmaceutical*

composition, it would be *prima facie* obvious to consider the variability of construction of said device which is indicated to achieve the same therapeutic end (Please refer to citations from the MPEP above).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Timothy E. Betton whose telephone number is (571) 272-9922. The examiner can normally be reached on Monday-Friday 8:30a - 5:00p. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Shengjun Wang/
Primary Examiner, Art Unit 1617

TEB